These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 12477578)

  • 1. Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis.
    Eriksen EF; Melsen F; Sod E; Barton I; Chines A
    Bone; 2002 Nov; 31(5):620-5. PubMed ID: 12477578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis.
    Ste-Marie LG; Sod E; Johnson T; Chines A
    Calcif Tissue Int; 2004 Dec; 75(6):469-76. PubMed ID: 15478000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
    Harris ST; Watts NB; Genant HK; McKeever CD; Hangartner T; Keller M; Chesnut CH; Brown J; Eriksen EF; Hoseyni MS; Axelrod DW; Miller PD
    JAMA; 1999 Oct; 282(14):1344-52. PubMed ID: 10527181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women.
    Zoehrer R; Roschger P; Paschalis EP; Hofstaetter JG; Durchschlag E; Fratzl P; Phipps R; Klaushofer K
    J Bone Miner Res; 2006 Jul; 21(7):1106-12. PubMed ID: 16813531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover.
    Borah B; Ritman EL; Dufresne TE; Jorgensen SM; Liu S; Sacha J; Phipps RJ; Turner RT
    Bone; 2005 Jul; 37(1):1-9. PubMed ID: 15894527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of high doses of oral risedronate (20 mg/day) on serum parathyroid hormone levels and urinary collagen cross-link excretion in postmenopausal women with spinal osteoporosis.
    Zegels B; Eastell R; Russell RG; Ethgen D; Roumagnac I; Collette J; Reginster JY
    Bone; 2001 Jan; 28(1):108-12. PubMed ID: 11165950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume.
    Fratzl P; Roschger P; Fratzl-Zelman N; Paschalis EP; Phipps R; Klaushofer K
    Calcif Tissue Int; 2007 Aug; 81(2):73-80. PubMed ID: 17612779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
    Seibel MJ; Naganathan V; Barton I; Grauer A
    J Bone Miner Res; 2004 Feb; 19(2):323-9. PubMed ID: 14969403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone safety with risedronate: histomorphometric studies at different dose levels and exposure.
    Recker RR; Ste-Marie LG; Chavassieux P; McClung MR; Lundy MW
    Osteoporos Int; 2015 Jan; 26(1):327-37. PubMed ID: 25304456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of risedronate on osteocyte viability and bone turnover in paired iliac bone biopsies from early postmenopausal women.
    Qiu S; Phipps RJ; Ebetino FH; Palnitkar S; Sudhaker Rao D
    Calcif Tissue Int; 2010 Nov; 87(5):392-7. PubMed ID: 20809096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography.
    Borah B; Dufresne TE; Chmielewski PA; Johnson TD; Chines A; Manhart MD
    Bone; 2004 Apr; 34(4):736-46. PubMed ID: 15050906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of risedronate in the treatment of osteoporosis.
    Geusens P; McClung M
    Expert Opin Pharmacother; 2001 Dec; 2(12):2011-25. PubMed ID: 11825332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seven years of treatment with risedronate in women with postmenopausal osteoporosis.
    Mellström DD; Sörensen OH; Goemaere S; Roux C; Johnson TD; Chines AA
    Calcif Tissue Int; 2004 Dec; 75(6):462-8. PubMed ID: 15455188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study.
    Palomba S; Manguso F; Orio F; Russo T; Oppedisano R; Sacchinelli A; Falbo A; Tolino A; Zullo F; Mastrantonio P
    Menopause; 2008; 15(4 Pt 1):730-6. PubMed ID: 18698280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risedronate for prevention and treatment of osteoporosis in postmenopausal women.
    Recker RR; Barger-Lux J
    Expert Opin Pharmacother; 2005 Mar; 6(3):465-77. PubMed ID: 15794737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risedronate for the prevention and treatment of postmenopausal osteoporosis.
    Cranney A; Waldegger L; Zytaruk N; Shea B; Weaver B; Papaioannou A; Robinson V; Wells G; Tugwell P; Adachi JD; Guyatt G
    Cochrane Database Syst Rev; 2003; (4):CD004523. PubMed ID: 14584020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential excessive suppression of bone turnover with long-term oral bisphosphonate therapy in postmenopausal osteoporotic patients.
    Iizuka T; Matsukawa M
    Climacteric; 2008 Aug; 11(4):287-95. PubMed ID: 18645694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience.
    Sorensen OH; Crawford GM; Mulder H; Hosking DJ; Gennari C; Mellstrom D; Pack S; Wenderoth D; Cooper C; Reginster JY
    Bone; 2003 Feb; 32(2):120-6. PubMed ID: 12633783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international.
    Reid DM; Hosking D; Kendler D; Brandi ML; Wark JD; Weryha G; Marques-Neto JF; Gaines KA; Verbruggen N; Melton ME
    Clin Drug Investig; 2006; 26(2):63-74. PubMed ID: 17163237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old.
    Boonen S; McClung MR; Eastell R; El-Hajj Fuleihan G; Barton IP; Delmas P
    J Am Geriatr Soc; 2004 Nov; 52(11):1832-9. PubMed ID: 15507059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.